Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 4/20 | 0.65 |
| ▸ | GRK1 | Q15835 | 2/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 9/20 | 0.57 |
| ▸ | SCD | O00767 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6302269 | 0.86 | MMP13 (0.60) | GRK2GRK1GRK5MMP13SCD | |
| SCHEMBL6298035 | 0.86 | MMP13 (0.64) | MMP13SCD | |
| SCHEMBL29065789 | 0.83 | GRK2 (0.65) | GRK2GRK1GRK5MMP13 | |
| SCHEMBL4969416 | 0.83 | GRK2 (0.65) | GRK2GRK1GRK5MMP13SCD | |
| SCHEMBL1500148 | 0.83 | GRK2 (0.65) | GRK2GRK1GRK5MMP13SCD | |
| SCHEMBL29723994 | 0.83 | GRK2 (0.65) | GRK2GRK1GRK5MMP13SCD | |
| SCHEMBL2491607 | 0.83 | MMP13 (0.64) | GRK2GRK1GRK5MMP13 | |
| SCHEMBL27660577 | 0.82 | MMP13 (0.63) | GRK2MMP13SCD | |
| SCHEMBL29692294 | 0.82 | SMN1; SMN2 (0.64) | GRK2GRK1GRK5TNFCYP11B1 | |
| SCHEMBL16210930 | 0.82 | SMN1; SMN2 (0.64) | GRK2GRK1GRK5TNFCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270849-A1 | Process for producing pyrimidin-4-one compound | UBE INDUSTRIES, LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| CN-1835930-A | Process for producing pyrimidin-4-one compound | UBE INDUSTRIES (JP) | 2006-09-20 | — | — | CN | disclosed |
| EP-1637523-A1 | PROCESS FOR PRODUCING PYRIMIDIN-4-ONE COMPOUND | Ube Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270849-A1 | Process for producing pyrimidin-4-one compound | DDC, ODC1, APRT | GRK2 2126/4885GRK1 1762/4885GRK5 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.